Federal Center of Nuclear Medicine Project Design and Development
Innovative solutions
We are constantly working to create and improve high-tech products and services in the field of nuclear medicine.
Perspectives for development
Our experts conduct scientific research and development using the latest technologies to achieve maximum efficiency and safety for patients and medical staff.
177Lu
225Ac
223Ra
The principle of radionuclide cancer therapy is the introduction into the human body of special medications that contain radionuclides.
Such drugs reach the affected areas directly, so the radiation is targeted (does not affect the entire body, but acts specifically on cancer sites).
Such drugs reach the affected areas directly, so the radiation is targeted (does not affect the entire body, but acts specifically on cancer sites).
The drug that is administered to the patient during radionuclide treatment accumulates in the affected area: the primary tumor or metastases. It irradiates the tumor, leading to its destruction. Surrounding tissues, healthy structures and the entire body are minimally affected.
Radium chloride, 223 Ra, solution for intravenous administration
Intended for radionuclide therapy of bone metastases in castration – resistant prostate cancer and the absence of visceral metastases.
177Lu-DOTATATE, solution for intravenous administration.
Radionuclide therapy of neuroendocrine tumors.
Hepatoren – MRNC, suspension for intra-arterial administration.
Intended for radioembolization of hepatocarcinoma and liver metastases.
*Joint development project with MRRC named after Tsyba, that is a branch of the National Medical Research Center of Radiology of the Ministry of health of the Russian Federation
*Joint development project with MRRC named after Tsyba, that is a branch of the National Medical Research Center of Radiology of the Ministry of health of the Russian Federation
Artroren- MRNC*, suspension for intra-articular admistration.
For radiosynovectomy of joint diseases.
*Joint development project with MRRC named after Tsyba, that is a branch of the National Medical Research Center of Radiology of the Ministry of health of the Russian Federation
*Joint development project with MRRC named after Tsyba, that is a branch of the National Medical Research Center of Radiology of the Ministry of health of the Russian Federation
Patents
Radiopharmaceutical composition for the treatment of inflammatory joint diseases based on radionuclide 188Re and human blood albumin microspheres. The composition and the method of its preparation.
Radiopharmaceutical drug for the treatment of primary hypatocellular carcinoma and metastatic formations in the liver.
The composition and the method of its preparation.
The composition and the method of its preparation.
Radiopharmaceutical preparation with rhenium -188 for the treatment of bone lesions of the skeleton.
Method of its preparation
Method of its preparation
2023 © All rights reserved
Zhivopisnaya St., 46, building 15, Moscow, Russia
Copying site materials is prohibited